Digital Trials Digest, our quarterly newsletter
As decentralized trials scale, central rating workflows must keep pace. Here's a clear look at what central rating is, where it fits in trial operations, and why integrated platform delivery is changing the way sponsors manage independent endpoint review.
The conversation at SCOPE 2026 wasn't about what's possible in clinical trials — it was about why it's still so hard to execute. Here's what we heard on the ground.
Discover how simplifying vaccine logistics can make scientific breakthroughs truly global — and why digital innovation is the missing link in equitable access.
The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.
Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.
When it comes to clinical trials, DCT and digital therapeutic (DTx) companies are natural partners. Both are tech savvy and adept in digital health
Decentralized clinical trials offer an effective avenue to mitigate the issues that typify pediatric clinical trials, including patient-reported data accuracy.
Though incidences of pneumonia have decreased overall, the disease is the leading infectious cause of death in children globally, affecting 1 in 6 child deaths.
In our conversations with trial sponsors, ObvioHealth often tackles common misconceptions about decentralized clinical trials (DCTs). These myths hinder our industry’s evolution by keeping sponsors from designing optimal trials that deliver better data with higher retention and compliance rates.